Granules India

Investment case

Value: integrated API-formulations

Why this business

Granules is a vertically integrated maker of high-volume generics (paracetamol, metformin, ibuprofen, guaifenesin) spanning APIs, pharmaceutical formulation intermediates (PFI) and finished dosages (FD). Q1FY27 revenue mix: FD 74%, API 13%, PFI 9%, CDMO 4%; North America 72%, Europe 16%, RoW 12%. Complex generics are now 50% of the FD portfolio (39% a year ago) and it ranks ~27th by US generic prescriptions (FY26). Senn Chemicals (Switzerland, acquired Apr-2025) gives it a peptide CDMO platform.

What we believe

1. 01Mix shift is real: complex generics 50% of FD (vs 39%), gross margin 65.6% and EBITDA margin 22.95% in Q1FY27 vs 20% a year ago; consensus expects 23% p.a. earnings growth.
2. 02Diversifying away from the US (72% of revenue): Europe +51% and RoW +56% YoY in Q1FY27 with a new EU-GMP certificate for Genome Valley.
3. 03Balance sheet fixed: net debt Rs 101 cr (0.07x EBITDA, from 0.34x at FY26), OCF Rs 387 cr in one quarter, ROCE 18%.
4. 04Pipeline: 25 ANDAs pending (USD 40 bn addressable brand value), second sole FTF (sodium oxybate ER, USD 267 mn brand); GPI Chantilly cleared with VAI in Apr-2026.
5. 05Peptide CDMO via Senn targeted at USD 50 mn revenue at 30%+ EBITDA margin; CDMO already 4% of sales, +106% YoY.

Why now

TTM PE 33.1x after a re-rating from ~Rs 487 (univest Apr-2026 note, 22x PE) to Rs 867; 5-yr average PE not sourced. EV/EBITDA computed on mcap + Rs 101 cr net debt over FY26 EBITDA. EV/EBITDA 18.2x; dividend yield 0.2%.

Market disagreement

• Divi's Laboratories: Divi's trades at a far higher multiple for its API/CDMO franchise; Granules at ~21x FY28E offers 30% EPS CAGR with its own (smaller) peptide CDMO option via Senn.
• Laurus Labs: Laurus's earnings depend on lumpy CDMO/ARV cycles and it carries more leverage; Granules is near net-debt-free (0.07x) with 23% EBITDA margins on a steadier finished-dosage base.

Position sizing

Value Small cap  0.7% of the PMS on $31 Jul 2026 (August rank not in top 30). Satellite positions are owned for an asymmetry, sized up when the cycle rewards risk and reduced when it does not.

Catalysts

• USFDA re-inspection and closure of the Gagillapur warning letter (timing unannounced as of Jul-2026).
• Sodium oxybate ER (sole FTF) approval/launch and further complex generic approvals from the 25 pending ANDAs.
• Senn peptide CDMO scale-up toward USD 50 mn revenue; Q2FY27 results (Nov-2026) to confirm 23%+ margins.

Risks and response

• Gagillapur (Hyderabad) USFDA warning letter (issued 26-Feb-2025) remains active pending re-inspection; 7 of 8 sites have clean EIRs but no re-inspection date (Jul-2026).
• Concentration: North America 72% of revenue and paracetamol/metformin-type molecules exposed to US price erosion and 26% reciprocal-tariff risk flagged by analysts.
• Management stepped back from its 24-25% EBITDA margin guidance in Q1FY27; promoter holding only 38% and down ~4pp over 3 years.

Thesis-break conditions

Not stated separately on this page; the risk list carries the monitoring triggers.

Review history

• 8 Sep 2026 · Yash Palod · one-pager in "Why We Own What We Own" (p44) · portfolio as of $31 Jul 2026
• 31 Aug 2026 · Classification in the August top-30: —

Source: Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026), p44. Internal; external publication of these fields is controlled by audience policy.